Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > INZY Inozyme Pharma > Detailed Quotes

INZY Inozyme Pharma

2.530
-0.070-2.69%
Close 10/04 16:00 ET
High
3.042
Open
3.042
Turnover
60.23K
Low
2.510
Pre Close
2.600
Volume
23.14K
Market Cap
101.57M
P/E(TTM)
Loss
52wk High
10.860
Shares
40.15M
P/E(Static)
Loss
52wk Low
2.300
Float Cap
27.07M
Bid/Ask %
-100.00%
Historical High
31.650
Shs Float
10.70M
Volume Ratio
0.50
Historical Low
2.300
Dividend TTM
--
Div Yield TTM
--
P/B
0.68
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.22%
Amplitude
20.45%
Avg Price
2.602
Lot Size
1
Float Cap
27.07M
Bid/Ask %
-100.00%
Historical High
31.650
Shs Float
10.70M
Volume Ratio
0.50
Historical Low
2.300
Dividend TTM
--
P/B
0.68
Dividend LFY
--
Turnover Ratio
0.22%
Amplitude
20.45%
Avg Price
2.602
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Inozyme Pharma engages in the research and development of novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Its lead product candidate is INZ-701, which is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
CEO: Mr. Axel Bolte
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...